Solvay Pharmaceuticals Withdraws Approval of Two New Drug Applications for LUVOX Tablets

Summary

Solvay Pharmaceuticals has voluntarily withdrawn its new drug applications for LUVOX tablets due to audit findings of possible inaccuracies in the chemistry, manufacturing, and controls section, allowing the FDA to continue approving abbreviated new drug applications for fluvoxamine maleate tablets.